Endotoxin-stimulated immune response to modified lymphoma cells.
Bacterial endotoxin was administered with iodoacetamide-modified P1798 lymphoma cells to immunize syngenic BALB/cJ mice against this lymphoma to which they are naturally unresponsive. Three or four vaccinations with endotoxin (6.6 mug/injection) alone or the modified cells alone did not produce host resistance. A significant number (30 percent) of mice receiving both endotoxin and modified cells rejected a subsequent implant of viable tumor cells. Even those mice having progressive tumor growth exhibited prolonged survival. High doses of endotoxin given with the modified P1798 cells caused 70-75 percent of the mice to reject the tumor implants. When resistance developed, antibodies reacting with tumor cell membrane were demonstrable. These results indicate that B-lymphocyte stimulators can produce an effective immune response against lymphoma cells.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis; D000951:Antigens, Neoplasm; D002462:Cell Membrane / Q000276:immunology; D004731:Endotoxins / Q000276:immunology*; D006084:Graft Rejection; D007460:Iodoacetamide / Q000494:pharmacology; D008223:Lymphoma / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000517:prevention & control; D014184:Transplantation, Homologous; D014611:Vaccination
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D004731:Endotoxins; D007460:Iodoacetamide